• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

    1.260 +0.010 (+0.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 426,825
    Open 1.250
    Bid (Size) 1.220 (2,000)
    Ask (Size) 1.280 (500)
    Prev. Close 1.250
    Today's Range 1.220 - 1.279
    52wk Range 0.8719 - 2.990
    Shares Outstanding 35,631,576
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
    From Biomea Fusion, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -6.0%
    -6.0%
    1 Month
    -3.1%
    -3.1%
    3 Month
    -18.2%
    -18.2%
    6 Month
    +3.3%
    +3.3%
    1 Year
    -22.7%
    -22.7%

    More News

    Read More
    News headline image
    Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib ↗
    Via Benzinga
    News headline image
    Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion to Participate at Upcoming Investor Conferences
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion to Participate at Upcoming Investor Conferences
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion to Participate at Jefferies London Healthcare Conference
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    News headline image
    Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
    From Biomea Fusion, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Biomea Fusion, Inc. - Common Stock publicly traded?
    Yes, Biomea Fusion, Inc. - Common Stock is publicly traded.
    What exchange does Biomea Fusion, Inc. - Common Stock trade on?
    Biomea Fusion, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Biomea Fusion, Inc. - Common Stock?
    The ticker symbol for Biomea Fusion, Inc. - Common Stock is BMEA on the Nasdaq Stock Market
    What is the current price of Biomea Fusion, Inc. - Common Stock?
    The current price of Biomea Fusion, Inc. - Common Stock is 1.260
    When was Biomea Fusion, Inc. - Common Stock last traded?
    The last trade of Biomea Fusion, Inc. - Common Stock was at 08/07/26 04:00 PM ET
    What is the market capitalization of Biomea Fusion, Inc. - Common Stock?
    The market capitalization of Biomea Fusion, Inc. - Common Stock is 44.90M
    How many shares of Biomea Fusion, Inc. - Common Stock are outstanding?
    Biomea Fusion, Inc. - Common Stock has 45M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.